Experimental HCV Drugs
Experimental HCV Drugs
EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies
- Details
- Category: HCV Treatment
- Published on Friday, 10 May 2013 00:00
- Written by Liz Highleyman
Achillion Pharmaceuticals' second-generation NS5A inhibitor ACH-3102 demonstrated potent activity against genotype 1a and 1b hepatitis C virus (HCV) and can be safely co-administered with the company's investigational protease inhibitor sovaprevir (formerly ACH-1625), according to studies presented at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
Sofosbuvir/Ledipasvir Coformulation Shows Good Early Response With or Without Ribavirin
- Details
- Category: HCV Treatment
- Published on Friday, 10 May 2013 00:00
- Written by Liz Highleyman
A dual regimen of sofosbuvir (formerly GS-7977) plus ledipasvir (formerly GS-5885) for 8 or 12 weeks produced 4-week post-treatment sustained virological response (SVR4) rates of 95% to 100% for both treatment-naive and previously treated hepatitis C patients in a small Phase 2 study, according to a recent announcement from Gilead Sciences, developer of both drugs.
EASL 2013: Vaniprevir Boosts Interferon/Ribavirin Response Rate for Prior Non-Responders with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Wednesday, 08 May 2013 00:00
- Written by Liz Highleyman
The next-generation HCV protease inhibitor vaniprevir (MK-7009) increased post-treatment sustained response rates for previously treated genotype 1 chronic hepatitis C patients with liver cirrhosis when added to pegylated interferon plus ribavirin, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
Direct-acting Antivirals Could Dramatically Reduce Hepatitis C Transmission among IDUs
- Details
- Category: HCV Treatment
- Published on Thursday, 09 May 2013 00:00
- Written by Liz Highleyman
Widespread use of new direct-acting antiviral agents (DAAs) for hepatitis C could dramatically lower the rate of HCV transmission among people who inject drugs in 3 hard-hit cities, according to a math model described in the March 28, 2013, issue of Hepatology.
They assumed that interferon-free regimens would produce 90% sustained virological response (SVR) with 12 weeks of treatment and would be available by 2015 -- all "realistic scenarios" based on the latest research.
AbbVie Interferon-free Hepatitis C Combo Gets FDA 'Breakthrough' Status
- Details
- Category: HCV Treatment
- Published on Tuesday, 07 May 2013 00:00
- Written by Liz Highleyman
An all-oral regimen of 3 new direct-acting antiviral agents, with or without ribavirin, has been designated by the U.S. Food and Drug Administration (FDA) as a "breakthrough therapy" for people with genotype 1 chronic hepatitis C, AbbVie (formerly Abbott) announced this week.
More Articles...
- EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients
- EASL 2013: HCV Protease Inhibitor Simeprevir Pushes Triple Therapy Cure Rate Up to 80%
- EASL 2013: Daclatasvir plus Interferon Cures More Genotype 2/3 Hepatitis C Patients
- EASL 2013: Sofosbuvir + Interferon/Ribavirin Cures 90% of People with Hard-to-Treat HCV Genotypes
Web Design and Development by